Xellia Pharmaceuticals, who have a focus on anti-infective treatments, has announced the formation of a new scientific advisory board.
The SAB will bring together international scientific and clinical advisors with expertise in infectious diseases, clinical microbiology, respiratory medicines and drug research and development.
Carl-Åke Carlsson, CEO of Xellia, said: “We welcome the members of the new scientific advisory board to the company.
“Their scientific and clinical insight and guidance combined with our specialist expertise will help us improve efficacy, increase safety profiles and reduce the side effects of existing molecules and develop new drugs to help tackle the global crisis of antimicrobial resistance.”
- Dr Andreas Rummelt, a member of Xellia Board of Directors supporting R&D
- Professor Gerhard Winter, Department of Pharmacy, Ludwig Maximilian University of Munich, Munich, Germany
- Professor Christoph Tang, The Sir William Dunn School of Pathology, University of Oxford, Oxford, UK
- Dr Tania Pressler, Chief Attending Physician, Rigshospitalet, Copenhagen, Denmark
- Professor Keith S Kaye, Division of Infectious Diseases and Department of Medicine at Wayne State University and Detroit Medical Center, Detroit, US
- Professor Anne O’Donnell, Professor and Chief, Division of Pulmonary, Critical Care, and Sleep Medicine, Georgetown University Hospital, Washington DC, US
- Professor Arjana Tambić Andrašević, Head of the Department of Clinical Microbiology at the University Hospital for Infectious Diseases, Zagreb, Croatia.
The board, chaired by Professor George Griffin, emeritus professor of infectious disease and medicine at St George’s, University of London, added: “Xellia has attracted an impressive board of scientific and clinical advisors, which I am proud to chair.
“Antimicrobial resistance is a huge area of unmet medical need and one of the greatest threats to human health. On behalf of the board, we look forward to working with and guiding Xellia in this valuable area of development.”